Catalog No.S1105 Synonyms: SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

15 Customer Reviews

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Lyn-PI3K-BTK signaling is required for the inhibitory effect of anti-CD180 on the activation of IFN-α signaling. (a and b) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), a Lyn inhibitor; LY294002 (5 μM), a PI3K inhibitor; ibturinib (1 μM), a BTK inhibitor; enzastaurin (1 μM), a PKC β inhibitor; U0126 (3 μM), an ERK inhibitor; SP600126 (2 μM), a JNK inhibitor or SB20358 (1 μM), a p38 inhibitor for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg/mL) or mouse IFN-α (1000 U/mL) for 4 h. qPCR analysis of the expression of IFIT1 (a) and MX1 (b). (c) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), LY294002 (5 μM), and ibturinib (1 μM) for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg mL−1) or mouse IFN-α (1000 U mL−1) for 40 min. Western blot analysis of the phosphorylation level of STAT-2. The data shown represent the mean values of three independent experiments, and the error bars represent the SEM. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA; ns denotes p > 0.05.

    Cell Mol Immunol, 2017, 14(2):192-202. LY294002 purchased from Selleck.

    The effects of GLP-1R siRNA and LY294002 on neurological score at 24 hours after subarachnoid hemorrhage (SAH) in Ex-4 treated rats.

    Neuropharmacology, 2018, 128:142-151. LY294002 purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

  • Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

    IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

  • PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.



    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

  • T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.



    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells M4noUGNmdGxiaX72ZZNqd25iYYPzZZk> MkHzNlQhcA>? NH\VPItKdmirYnn0bY9vKG:oIHXwbZRp\WyrYXyg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGOnbHygcYloemG2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmNWmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JINmdGxiaX72ZZNqd25iYYPzZZktKEmFNUC9NE4{QCEQvF2u MUKyNlgxPDFyOB?=
Sf21 cells MVPGeY5kfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKG2xdYPlJJdqdGRidInw[UBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NF0xNjVizszN NGHCcXkzOjV{ME[zNC=>
Sf21 cells Mn3ESpVv[3Srb36gZZN{[Xl? NVvkfnJxUW6qaXLpeIlwdiCxZjDtc5V{\SC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmNlEh[2WubIOsJGlEPTB;MD61JO69VS5? NWTNSnRCOTl5NEiyOlk>
Sf9 cells MXHGcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> NWG5PWk5UW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD61OUDPxE1w NYHzTWZNOjFzMkG2N|E>
THP1 cells NF3OTlZHfW6ldHnvckBie3OjeR?= NHr1N5pKdmirYnn0bY9vKG:oIGPDSlEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvODFizszNMi=> NIXqZXIyPjd6OUe0Ni=>
human PC3 cells Mk[4SpVv[3Srb36gZZN{[Xl? MV6zNEBucW5? NY\xdZp7UW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IIPldolv\SB2N{OgZYZ1\XJiM{CgcYlveyCkeTDFUGlUSSxiSVO1NF0yNjQQvF2u M4LGT|I{PDFyMEC1
HeLa (human carcinoma) cells. MnjRSpVv[3Srb36gZZN{[Xl? NWHsNoVYUW5idnn0do8hcW6qaXLpeIlwdiCxZjDEUmEu\GWyZX7k[Y51KHC{b4TlbY4hc2mwYYPlLGRPSS2SSzmg[pJwdSCKZVzhJEhpfW2jbjDjZZJkcW6xbXGpJINmdGy|LDDJR|UxRTFwNDFOwG0v MWmxOVY2QDh5MB?=
THP1 cells M1X2[WZ2dmO2aX;uJIF{e2G7 NEH4ZWVKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvPjVizszNMi=> MmXFNVY4QDl5NEK=
HeLa cells NHXjXo1HfW6ldHnvckBie3OjeR?= NWXFPXZ7UW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w NVK3bWJYOTV4NUi4O|A>
human MCF7 cells MoK5R5l1d3SxeHnjxsBie3OjeR?= MkXHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVIvPjNizszNMi=> NYXlN5RmOTh4OUG4PVQ>
HeLa cells NV:1eYxVTnWwY4Tpc44h[XO|YYm= M1TyRWlvcGmkaYTpc44hd2ZiQWitO|UxOyCkaX7kbY5oKHSxIILlZ49u[mmwYX70JHBtczNiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[nliV3XzeIVzdiCkbH;0MEBKSzV;MzFOwG0v NWPKUppvOTdzM{WyOFg>
human MCF7 cells MmDXR5l1d3SxeHnjxsBie3OjeR?= MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zMlA5KM7:TT6= NFLINXAyQDZ7MUi5OC=>
human MCF7 cells NWf1XIhMS3m2b4TvfIlkyqCjc4PhfS=> M1T0bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliU2LCJIF{e2G7LDDHTV0{NjF4IN88UU4> NV7YcINJOTh4OUG4PVQ>
human MDA-MB-231 cells MmrZR5l1d3SxeHnjxsBie3OjeR?= NGPOcIdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLPUOuN|Ih|ryPLh?= MWSxPFY6OTh7NB?=
human MDA-MB-231 cells MXzDfZRwfG:6aXRCpIF{e2G7 NU\UbHJjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCxNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9OE4{PSEQvF2u NHKwXFUyQDZ7MUi5OC=>
human MDA-MB-468 cells MVrDfZRwfG:6aXRCpIF{e2G7 Mn\ZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW|ZX7j[UBw\iB{MDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYpvwKwhUUN3ME20Mlc3KM7:TT6= M{HzelE5PjlzOEm0
human HCT116 cells MmTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1SwOFQ5KGh? NW\lWWZpT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NT6zJO69VQ>? M1XTVlIzOjF{N{Kx
human HCT116 cells NFLVNphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEm3bYs1QCCq MUnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlgh|ryPLh?= M4rpd|IzOjF{N{Kx
HeLa cells M4L1SGJqdmSrbnegZYZncW6rdImgZZN{[Xl? NFj6cIZDcW6maX7nJIFn\mmwaYT5JIZweiCSSUOtb4lv[XOnIHnzc4xifGWmIH\yc40hUGWOYTDj[YxteyxiS3m9OkDPxE1? MVexOVY2QDh5MB?=
human HCT116 cells MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHfRd201QCCq MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Nj63JO69VS5? MorsNlIzOTJ5MkG=
MDA-MB-231 cells M{nNZmN6fG:2b4jpZ:Kh[XO|YYm= NYLyb4plS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v M2jTO|E5PjlzOEm0
Sf9 cells NFLvNmlHfW6ldHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKEONMjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{NCCLQ{WwQVYvQSEQvF2u NYG5S3V1OTh|MkG3NVY>
human U87MG cells NU\6N3FwTnWwY4Tpc44h[XO|YYm= NUH3cYU6UW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6= NV\OUFFbOTh|NEW2NFk>
human MDA-MB-468 cells M1frdGN6fG:2b4jpZ:Kh[XO|YYm= M3LjRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUiuNkDPxE1w NGrXfHcyQDZ7MUi5OC=>
human A375 cells M3j1b3Bzd2yrZnXyZZRqd25iYYPzZZk> MlWyOFYhcA>? NUD2Z5JVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> NXLhbIJUOTdyNEmyOFg>
human A375 cells M1;mcnBzd2yrZnXyZZRqd25iYYPzZZk> MmnQTY5pcWKrdHnvckBw\iC|ZYL1cU1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iQUO3OUBk\WyuczygTWM2OD16LkSg{txONg>? MUOxO|YxOTd|OR?=
human HL60 cells MX7DfZRwfG:6aXRCpIF{e2G7 M2HiUFczKGh? NUDCbmJ6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvQTRizszNMi=> NFLNTVAzOjR6MEi1NS=>
mouse Raw264 macrophage NEjRU|dHfW6ldHnvckBie3OjeR?= MkSwTY5pcWKrdHnvckBw\iCFNXGtcYVlcWG2ZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2ViUnH3NlY1KG2jY4LvdIhi\2VuIFnDOVA:OTBizszNMi=> MlqxNVY4QDl5NEK=
Sf9 cells NWDBO2tZTnWwY4Tpc44h[XO|YYm= NYPOfFVGUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJIJwfmmwZTDQTVNMKGW6cILld5Nm\CCrbjDT[lkh[2WubIOsJGlEPTB;MUCg{txONg>? MWqxNFk6QDN3MR?=
human MDA-MB-468 cells MYjDfZRwfG:6aXRCpIF{e2G7 M17KTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVExNjRizszNMi=> NYHONY5VOTh4OUG4PVQ>
human PC3 cell NFKyNYZRem:uaX\ldoF1cW:wIHHzd4F6 NVTHVJdnPzJiaB?= NVXSdXRCUW6qaXLpeIlwdiCxZjDoeY1idiCSQ{OgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;MUKuNUDPxE1w NYGyVXk{OjN2MUCwNFU>
human HL60 cells NFG5U|VRem:uaX\ldoF1cW:wIHHzd4F6 M{XYZVczKGh? NUXSVY9[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG4MlQ{KM7:TT6= NIj0NVEzPTZ7M{e4Oy=>
human BT474 cell MXTQdo9tcW[ncnH0bY9vKGG|c3H5 M3vnT|czKGh? NYLhW2V1UW6qaXLpeIlwdiCxZjDoeY1idiCEVES3OEBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd-+9lCCLQ{WwQVIxNjdizszNMi=> MV2yN|QyODByNR?=
THP1 cells MXvGeY5kfGmxbjDhd5NigQ>? NFyxTFdKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBkcGWvb4ThfIl{KG:oIGTIVFEh[2WubIOsJGlEPTB;M{eg{txONg>? NF\Z[JUyPjd6OUe0Ni=>
human 184B5 cells MnSyR5l1d3SxeHnjxsBie3OjeR?= NXH0OphOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOTh2QkWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUO5MlM4KM7:TT6= NHzyN|YyQDZ7MUi5OC=>
human KB cells M13IfWN6fG:2b4jpZ:Kh[XO|YYm= NYW4T2FrPzJiaB?= NHm4W2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUS0Mlc3KM7:TT6= MUSyNVk1PTJ3MB?=
mouse RAW264.7 cells MkTpSpVv[3Srb36gZZN{[Xl? MVKyOUDPxE1? NWjiOGJPOjBiaB?= Mo\PTY5pcWKrdHnvckBw\iCSSUPLM2FMXCCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2OgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDJ3IN88UUBi\nSncjCyNEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MW[yOFI6QTZzNh?=
human A2780 cells MWHBdI9xfG:|aYOgZZN{[Xl? MVGyJO69VQ>? MYmxNkBp MYrJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHPpd5Bt[XSrbj3y[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSWu2IHzleoVtKGG2IEKgeW0h[W[2ZYKgNVIhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZMv M2\aT|E4Pjh2MEG4
human SW480 cells MXjGeY5kfGmxbjDhd5NigQ>? NYS4cXBpOjBizszN NILvSWozPCCq M4XiWWRm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm|aYO= M3nqWlE4PDd{OU[y
mouse mast cells NW\zUmhnTnWwY4Tpc44h[XO|YYm= NE\ON|QzOCEQvF2= MX7Jcohq[mm2aX;uJI9nKFOFRj3pcoR2[2WmIGDLRk9Cc3RicHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKG2jc4SgZ4VtdHNiYYSgNlAh|ryP NYnkNG9NOTZ5OEm3OFI>
human BJ cells NYLaN5psTnWwY4Tpc44h[XO|YYm= MWGyOUDPxE1? MnSyNkBp MYXJcohq[mm2aX;uJI9nKFCLM1ugd4lodmGuaX7nJIlvKFCGR1[td5RqdXWuYYTl[EB{\XK3bTDzeIFzfmWmIHj1cYFvKEKMIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheGyjc33p[EBGT0[SL2DIJIRwdWGrbjDv[kBCc3RiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiUFitSWdHWCC{ZXTpd5RzcWK3dHnvckB1dyCybHHzcYEhdWWvYoLhcoUh[XRiMkWgeW0hfHKnYYTl[EAzKGi{czDi[YZwemViUFTHSkBkcGGubHXu[4Uh[nliY3;u[o9k[WxibXnjdo9{[2:yeR?= NITabpUyPjd4N{C4OS=>
human IGROV1 cells MYDGeY5kfGmxbjDhd5NigQ>? M{HZeFI1NzR6IHi= MXHJcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NYrFUHRKOjF{MU[xOVE>
human IGROV1 cells MmDrSpVv[3Srb36gZZN{[Xl? NWq1[XRXOjRxNEigbC=> M2ixR2lvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M2GzNVIyOjF4MUWx
rat RBL2H3 cells MV\GeY5kfGmxbjDhd5NigQ>? NXXqZnFvUW6qaXLpeIlwdiCxZjDBNlMyQDdvaX7keYNm\CCmZXfyZY52dGG2aX;uJIlvKHKjdDDSRmwzUDNiY3XscJM> MojmNVg{Ojh5MU[=
human BJ cells NWLlR3VjTnWwY4Tpc44h[XO|YYm= NV3mcndMOjVizszN NFXHWI4zKGh? MlXORYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> NV7vVZc5OTZ5NkewPFU>
human HCT116 cells M2HFPWZ2dmO2aX;uJIF{e2G7 MWexNEDPxE1? NFT3VJcyOCCvaX6= MXHJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> MWeyNlIyOjd{MR?=
human HCT116 cells Mo\YSpVv[3Srb36gZZN{[Xl? NUf2UpJCOTBizszN NGnqN2QyOCCvaX6= MlfjTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNidYPpcochYzN{UG3BWHAh[XRiMUCgeW0h[W[2ZYKgNVAhdWmwcx?= NETyepozOjJzMkeyNS=>
human HCT116 cells NHLHOG1HfW6ldHnvckBie3OjeR?= NIjpNpgyOCEQvF2= NXfmenJ{UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= NVnqRZM{OjJ{MUK3NlE>
human HCT116 cells NVi4bnl6TnWwY4Tpc44h[XO|YYm= M3XYclExKM7:TR?= NI\hS4tKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDINVA1P1JibYX0ZY51KGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHH0JFExKHWPIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> M3W1T|IzOjF{N{Kx
human PC3 cells NW\zV5poTnWwY4Tpc44h[XO|YYm= MX21NEDPxE1? MXK4JIg> Mkj0TY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= MmjjNlI6QTh2N{K=
human LNCAP cells M2O0cGZ2dmO2aX;uJIF{e2G7 NIroVIkxNjFvM{Cg{txO MoLpN|AhdWmw MnOyTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M1naO|IzQDN{M{G2
human LNCAP cells NHf6XYpHfW6ldHnvckBie3OjeR?= NF7SbmoxNjFvM{Cg{txO MoKyNlQhcA>? M1;l[WRwf26{ZXf1cIF1cW:wIH;mJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MXOyNlg{OjNzNh?=
HUVEC NXWwVoJRTnWwY4Tpc44h[XO|YYm= MmT6NVAuOjVizszN MoXSNVYhcA>? NGr0d5dKdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgTWNCVS1zIH3SUmEh\XiycnXzd4lwdiCrbjDIWXZGSyCjdDCxNEB1dyB{NTD1UUBxemW2cnXheIVlKG[xcjCxOkBpenNiYnXmc5JmKFSQRnHsdIhiKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkA3KGi{czDifUBTXC2SQ2KgZY5idHm|aYO= MmjHNlIxOjZ2MUC=
HUVEC Mnn5SpVv[3Srb36gZZN{[Xl? MWCxNE0zPSEQvF2= MYizNEBucW5? NHT1dZVKdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgbJVu[W5iSVPBUU0yKHC{b33veIVzKGGldHn2bZR6KGW6cILld5Nm\CCrbjDIWXZGSyCjc4Pld5Nm\CCjczDi[ZRiNWejbHHjeI9{cWSjc3WgZYN1cX[rdImgZZQhOTBidH:gNlUhfU1icILleJJm[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgWG5H[WyyaHGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> M2XOPVIzODJ4NEGw
human H1299 cells M4TaOGZ2dmO2aX;uJIF{e2G7 MWSwMlEuOzBizszN NInDVpkzPCCq NU\X[Wl4TG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MkW0NlI3OjJyNkm=
human H1299 cells NFzD[otHfW6ldHnvckBie3OjeR?= MlW0NE4yNTNyIN88US=> NGTKVWYzPCCq MkO5SI94diC{ZXf1cIF1cW:wIH;mJINKSVB{IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gNVAxKHWpL33sJHRTSUmOIHHu[EBRUTONIHnubIljcXSxcjDMXVI6PDByMh?= NEi1TlczOjZ{MkC2PS=>
human H1299 cells MknGSpVv[3Srb36gZZN{[Xl? Mn3vNE4yNTNyIN88US=> NHHm[3UzPCCq Mmq1TY5lfWO2aX;uJI9nKESUNTDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MnyyNlI3OjJyNkm=
human H1299 cells M3f3TWZ2dmO2aX;uJIF{e2G7 NFXaXHgxNjFvM{Cg{txO NVHYfFRHOjRiaB?= MWPJcoR2[3Srb36gc4YhUk6NLX3l[IlifGWmIFPIU3Ah\XiycnXzd4lwdiCrbjDoeY1idiCKMUK5PUBk\WyuczDheEAxNjFidH:gN|AhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NH;ZXFgzOjZ{MkC2PS=>
HEK293 cells NF7YVolHfW6ldHnvckBie3OjeR?= MVuxMlUhcA>? MXzEbZNxdGGlZX3lcpQhd2ZiW{PIYWxUTCCocn;tJIh2dWGwIEXIWFYhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bi\nSncjCxMlUhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5o M1\EWlIzPTN5MUWz
human U251HRE cells M2TKSGZ2dmO2aX;uJIF{e2G7 M{m2fGlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkGgZYN1cX[jdHnvckBqdiCqdX3hckBWOjVzSGLFJINmdGy|IHL5JINmdGxiYnHz[YQhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NGfvcXAyQDVyMU[wNS=>
human HCT116 cells M{DMUmZ2dmO2aX;uJIF{e2G7 NGXiN2gyOCEQvF2= MlHKTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> NFK2UXczOjJzMkeyNS=>
Sf9 cells NFmxZWtndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? NUXBZm5EUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYm= NEH2eZEzOTF{MU[zNS=>
human HCT116 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 MVK3NkBp MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13MT64NkDPxE1w MXOyOVY6Ozd6Nx?=
human HCT116 cells MlLqR5l1d3SxeHnjxsBie3OjeR?= M3nqXFczKGh? MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Ok4xOSEQvF2u Mn2zNlE6PDV{NUC=
human PC3 cells M1fWZWN6fG:2b4jpZ:Kh[XO|YYm= NUCzdW1TPzJiaB?= MkXBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= NIT0[oozOjR6MEi1NS=>
human HuH7 cells MmrwVJJwdGmoZYLheIlwdiCjc4PhfS=> MX63NkBp MlS4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKdVi3JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTZ5LkG4JO69VS5? M{\mO|I2Pjl|N{i3
human A549 cells MoryVJJwdGmoZYLheIlwdiCjc4PhfS=> NVnSbIFJPzJiaB?= MmLvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXLzc5Jj[W6lZTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTh{LkOyJO69VS5? MX:yOVY6Ozd6Nx?=
human A549 cells M1qzfmN6fG:2b4jpZ:Kh[XO|YYm= MUm3NkBp MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= M2TRZlIzPDhyOEWx
human PC3 cells NXvyOpQ1WHKxbHnm[ZJifGmxbjDhd5NigQ>? Ml7DNlUh|ryP MVmxNlAhcA>? MlLURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYYSgNlUhfU1iYX\0[ZIhOTJyIHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gSG1UVw>? NG\zRYoyPjZ6MEG1PS=>
human H460 cells NHzXS4tHfW6ldHnvckBie3OjeR?= MnzhN|Ah|ryP M{TjNGlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJPDZyIHPlcIx{KGG|c3Xzd4VlKGG|IFHreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{IES3N{B2eCC2bzCzNEB2VQ>? NVHLRW4yOTh3MEG2NFE>
human IGROV1 cells MYPGeY5kfGmxbjDhd5NigQ>? MoHTNlQhcA>? MkPVR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDCxJIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? NHPSUGUzOTJzNkG1NS=>
human IGROV1 cells NYXpUmozTnWwY4Tpc44h[XO|YYm= M2TyO|I1KGh? NX\aZ|k{S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEA2KG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= M2H4OVIyOjF4MUWx
human H4 cells MlXSSpVv[3Srb36gZZN{[Xl? M3\4PFIhcA>? MY\E[YNz\WG|ZTDpckBHYV[HLWLGVEshfmW|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?= M3fnTFE5ODJ2NUi0
human MGC803 cells M1X4e2Z2dmO2aX;uJIF{e2G7 NHXNRmIzPSEQvF2= MUi0PEBp NEizOm9E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOT0N6MEOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhOjVidV2gZYZ1\XJiNEigbJJ{KHW|aX7nJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZYZ1\XJiNEigbJJ{KGK7IH\sc5ch[3m2b33leIVzKHKnbHH0bZZmKHSxIHPvcpRzd2x? MmPoNlQyOTl6Nkm=

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
E-cadherin / p-Akt / Akt; 

PubMed: 29731993     

Immunoblot analysis of E-cadherin, P-AKT, and AKT in SNU-C5/5-FU cells treated with LY294002 (20 μM).

beta-catenin / p-GSK3β / Cyclin D1; 

PubMed: 29731993     

Immunoblot analysis of P-AKT, AKT, β-catenin, P-GSK-3β, GSK-3β, and cyclin D1 in SNU-C5/5-FU cells treated with LY294002 (20 μM).

Bcl-xl / Bax / caspase3 / cleaved caspase-3; 

PubMed: 25344912     

Four esophageal cancer cell lines were treated with different concentrations of LY294002 for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin; 

PubMed: 23251002     

HT29, Colo205, and RKO cells were treated for 2 h with PLX4720, LY294002 or their combination at indicated concentrations. Cell lysates were subjected to western blot analysis with antibodies against phosphorylated or total forms of AKT or ERK1/2, and antibodies against p-P70S6K, pGSK3β or vinculin.


PubMed: 20649566     

Typical Western blot showing that basal pPKB-S473 was reduced by increasing concentrations of LY294002 (upper panel). Pre-incubating 10 µM of the MEK-1/2 inhibitor U0126 induced pPKB–S473 levels which were reduced when rising concentrations of LY294002 were added. A full suppression of pPKB–S473 below the detection limit was seen at 30 µM PI3K inhibitor (10 µM U0126 + 30 µM LY294002). β-Actin immunoreaction served as loading control.

29731993 25344912 23251002 20649566
Growth inhibition assay
Cell viability; 

PubMed: 25344912     

MTT assay was used to determine the effects of different concentrations of LY294002 on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

α-SMA / CD31; 

PubMed: 27671604     

Immunofluorescence analysis for the expression levels of CD31 and α-SMA in Control, LY294002, As2O3 and As2O3 + LY294002 groups. Scale bar = 30 μm. (in HAECs).

E-cadherin / beta-catenin; 

PubMed: 29731993     

The localization of E-cadherin and β-catenin were confirmed by confocal microscopy. Scale bars, 20 μm.

COX-2 / p-NFκB; 

PubMed: 29731993     

The localization of Cox-2 and P-NF-κB was confirmed by confocal microscopy. Scale bars, 20 μm.


PubMed: 18388194     

C2C12 cells were plated into two-well chamber sliders for 24 h and then treated with 20 μm LY294002 or the same amount of vehicle (ethanol) for 16 h. Cells were fixed and FOXO3a was stained. LY294002 treatment activates FOXO3a and leads its translocation into the nucleus.

27671604 29731993 18388194
IL-10 / IL-1β / TNFα / IL-6; 

PubMed: 22208359     

Microglial cells were pre-treated with LY294002 for 1 h and then stimulated with LPS (100 ng/ml) or PIC (10 μg/ml) for 16 h. ELISA were performed. All values were normalized to those obtained in cultures stimulated with LPS or PIC without LY294002 (= 1). At least 3 cases were analyzed for each experiment, and statistics were performed using t-test comparing values with vs. without LY294002.

In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]


Kinase Assay:


+ Expand

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:


+ Expand
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Formulation: Dissolved in DMSO plus 0.25 ml of PBS
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34


CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • Answer:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • Question 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID